Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 5/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6380228 | 0.96 | KMT2A (0.41) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL31389495 | 0.91 | RIPK1 (0.44) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL6382710 | 0.87 | NPC1 (0.43) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL6379779 | 0.81 | RIPK1 (0.41) | KDM4ERIPK1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL31390102 | 0.80 | KMT2A (0.39) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL31389399 | 0.80 | KMT2A (0.39) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL31389789 | 0.79 | KMT2A (0.46) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL31389773 | 0.77 | RIPK1 (0.47) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL31389815 | 0.77 | RIPK1 (0.47) | NPC1RAB9AKDM4ERXFP1KMT2A | |
| SCHEMBL2928372 | 0.76 | NPC1 (0.43) | NPC1RAB9AKDM4ERXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-6831074-B2 | Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders | PFIZER INC | 2004-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | NPC1 3153/4885RAB9A 436/4885KDM4E 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.